TAE Life Sciences Signs Biddle Sawyer to Manufacture Boronated TC220 Drug for BNCT Cancer Treatment

Posted on by

TC220 is a proprietary boronated amino acid analog developed by TAE Life Sciences to support BNCT cancer treatment and will be manufactured exclusively by Kinentia Biosciences for the US market IRVINE, Calif., Aug. 15, 2023 /PRNewswire/ — TAE Life Sciences has today announced a landmark…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.